Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455494 · ClinicalTrials.gov registry record · Phase 1
Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial
A Phase 1 study of Malaria, sponsored by Tulane University Health Sciences Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00455494 is a Phase 1 study of Malaria that has completed, run by Tulane University Health Sciences Center. The registered enrollment target is 14 participants, below the 258-participant average among 27 other Malaria trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00455494, a Phase 1 study of Malaria, has completed, sponsored by Tulane University Health Sciences Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety of a 2100 mg dose of AQ-13, a new candidate antimalarial active against drug-resistant P. falciparum infection, and to determine the effect of a standard fatty meal on the absorption of the drug from the gut and its blood levels.
Conditions Studied
Interventions
- DRUG AQ-13
Study Locations (1)
Louisiana
- Tulane-LSU General Clinical Research Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00455494
The ClinicalTrials.gov registry entry for NCT00455494 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 258-participant average among 27 other Malaria trials with a reported enrollment target (95% lower). The listed sponsor is Tulane University Health Sciences Center, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malaria appearing as the primary indexed condition, and to 1 intervention - of which AQ-13 is the first listed.
NCT00455494 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT00455494 about?
NCT00455494 is a clinical study titled "Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial". The purpose of this study is to test the safety of a 2100 mg dose of AQ-13, a new candidate antimalarial active against drug-resistant P. falciparum infection, and to determine the effect of a standard fatty meal on the absorption of the drug from the gut and its blood levels.
What is the current status of trial NCT00455494?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2005-01. Estimated completion is 2006-12.
What conditions does trial NCT00455494 study?
This clinical trial studies the following conditions: Malaria.
What interventions are being tested in trial NCT00455494?
The interventions under investigation include: AQ-13 (DRUG).
Who is sponsoring clinical trial NCT00455494?
This trial is sponsored by Tulane University Health Sciences Center, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00455494 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral E1018 in Healthy Adult Participants
RECRUITING · Phase 1
-
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
RECRUITING · Phase 1
-
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
ACTIVE NOT RECRUITING · Phase 1
-
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
ACTIVE NOT RECRUITING · Phase 1
-
Trial to Evaluate CIS43LS in Healthy Adults
COMPLETED · Phase 1
-
Blood-Stage Plasmodium Vivax Cell Bank
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.